In Reply We are delighted to learn of Geisler and Ghosh’s interest in treating alcohol dependence and welcome the opportunity to address some of their misunderstandings about our report of a randomized clinical trial of gabapentin for the treatment of alcohol dependence.1 Contrary to their concern that ours was initially a 2-arm trial, our original protocol in fact specified a 3-arm dose-ranging design (gabapentin, 1800, 900, and 0 mg/d) and was reviewed as such by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the Scripps institutional review board, and the JAMA Internal Medicine (JAMA-IM) statistical reviewer (per JAMA-IM’s requirement that the original protocol be included with a clinical trial submission), and the clinicaltrials.gov link referenced by the authors specifies “dose ranging.”
Mason BJ, Goodell V, Shadan F. Gabapentin Treatment for Alcohol Dependence—Reply. JAMA Intern Med. 2014;174(7):1201–1202. doi:10.1001/jamainternmed.2014.1591
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: